Entrepreneurship

CARB-X

The Growing Antimicrobial Resistance Challenge

Antimicrobial resistance (AMR) is a major threat to Public Health. According to the World Health Organization, there are an estimated 700,000 deaths worldwide each year as a result of bacterial infections. The US Center for Disease Control and Prevention (CDC) estimates that in the US alone, 23,000 people die each year from drug-resistant bacterial infections.

Global Movement to Combat Antimicrobial Resistance

CARB-X is one of the world’s largest public-private partnerships dedicated to accelerating antibacterial innovation. It has the world’s largest antibacterial pipeline focused specifically on combating drug resistant bacteria, especially Gram-negative bacteria, and it supports research projects in companies around the world. CARB-X is investing more than $500 million between 2016-2021 in the development of antibiotics and other life-saving therapeutics of all types, diagnostics, vaccines and other preventatives and devices. California Life Sciences Institute (CLSI) is a vital part of CARB-X’s network of accelerators and provides business and technical support to funded projects throughout the world.

To learn more about CARB-X and funding opportunities, please consult the CARB-X website at https://carb-x.org/
CLSI is developing a resource network of subject-matter expertise: infectious disease (both R&D and clinical experience), regulatory, reimbursement, preclinical development, health economics, competitive intelligence, technical expertise with diagnostics and devices, partnering, finance and operations and commercialization strategy, among others. If you wish to join the global fight against antimicrobial resistance, please contact Amy Xu.
CLSI want to hear from all potential funding sources with interest in companies developing products in the antimicrobial resistance (AMR) space. Please contact Amy Xu.
If you are interested in licensing or collaboration opportunities with companies in the AMR space, please contact Amy Xu.
Please contact Lori Lindburg about opportunities to sponsor CLSI events focused on AMR, such as research conferences, panel discussions, partnering programs, and networking events bringing the AMR community together.
The CARB-X Portfolio
CARB-X support is restricted to projects that target drug-resistant bacteria highlighted on the CDC’s Antibiotic Resistant Threats list, or the Priority Bacterial Pathogens list published by the WHO in 2017 – with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list. The development stages that are in scope for CARB-X range from target/candidate identification and characterization through Phase 1 clinical trials.
CARB-X and its Partners Accelerate Product Development for AMR: Funding, Entrepreneurial Support and In-Kind R&D Services
CARB-X is investing more than $500 million between 2016 and 2021 to accelerate the early development of innovative antibacterial products.
CLSI in the Bay Area, MassBio in Cambridge, and the Wellcome Trust in the UK serve as accelerators for CARB-X companies. Through our networks of volunteer subject-matter experts, the accelerators provide entrepreneurial support and business mentoring to companies in the CARB-X portfolio, regardless of location.
NIAID and RTI offer a range of in-kind pre-clinical services, study design and regulatory support to product developers, and the Broad Institute has created an inter-disciplinary center to partner with academic investigators with a goal of advancing at least three therapeutic antibiotic products through shared chemistry services.
What is CARB-X
CARB-X is the world’s largest public-private partnership devoted to supporting early development antibacterial R&D. Funded by ASPR/BARDAWellcome Trust, the UK Government Department of Health and Social Care (DHSC)’s Global AMR Innovation Fund (GAMRIF), and the Bill & Melinda Gates Foundation, with in-kind support from NIAID, CARB-X is investing more than $500 million from 2016-2021 to support the development of innovative therapeutics, vaccines, diagnostics, devices and other life-saving products. CARB-X supports research focused on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is headquartered at the Boston University School of Law. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI). www.carb-x.org.
We would be happy to answer your questions about CARB-X and share more ways you can get involved.
Amy Xu
Program Associate
axu@califesciences.org

Assistant Secretary for Preparedness and Response Barda Wellcome Trust NIH NIAID
California Life Sciences Institute Mass Bio Boston University RTI Broad Institute